Strategic Growth NCM-USA aims to become a leading distributor of radiopharmaceuticals for Molecular Imaging and Targeted Radionuclide Therapy within 3-5 years, signaling a potential expansion in sales partnerships, distribution agreements, and cross-selling of related imaging agents and services.

Integrated Capabilities The redesigned facility supports both diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals, with GMP production, multiple cyclotrons, hot cells, automated modules, and QC labs, suggesting opportunities to upsell full-service manufacturing, regulatory support, and turnaround efficiency to pharma and clinical trial customers.

Clinical Trial Support Active involvement in supporting INDs for diagnostic and therapeutic studies indicates potential demand for collaboration on radiopharmaceutical development, including manufacturing for early-phase trials and ongoing supply for investigational programs.

Competitive Differentiation Capacity to produce multiple radiopharmaceuticals simultaneously with a dedicated chemist and radiopharmacist team positions NCM-USA as a reliable partner for clinics and institutions needing versatile, scalable production for diverse PET and theranostic workflows.

Small to Mid Market Focus With 11-50 employees and revenue in the lower-to-mid single-digit millions, there is an opportunity to tailor cost-effective, scalable service packages and educational outreach to mid-sized clinics, research institutes, and regional distributors seeking entry or expansion in radiopharmaceutical manufacturing and distribution.